Year None202320222021202020192018 Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights May 09, 2023 Read More Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody Apr 20, 2023 Read More Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023 Apr 18, 2023 Read More Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference Apr 13, 2023 Read More Sensei Biotherapeutics to Participate in Cantor Fitzgerald’s Future of Oncology Virtual Symposium Mar 30, 2023 Read More Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights Mar 28, 2023 Read More Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody Mar 21, 2023 Read More Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023 Mar 14, 2023 Read More Sensei Biotherapeutics Adopts Stockholder Rights Agreement Mar 07, 2023 Read More Sensei Biotherapeutics to Participate in Oppenheimer’s 33rd Annual Healthcare Conference Mar 06, 2023 Read More Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 15
